India’s Pharma Industry: Poised for Global Expansion by 2030

India’s pharmaceutical industry is on the verge of major expansion, with its share in the global market predicted to climb to 5% by 2030, according to a new report from Bain & Company. Currently valued at about USD 55 billion, the Indian pharma sector is projected to grow 2.2 to 2.4 times over the next six years, reaching between USD 120 billion and USD 130 billion.

The report emphasized the robust nature of India’s pharma market, noting that it could approach USD 450 billion by 2047. Although India currently contributes only 3% to 3.5% of the global pharmaceutical market, which is valued at approximately USD 1.6 trillion, the anticipated growth highlights India’s increasing prominence as a vital player in the global landscape.

Uniquely, India’s pharma exports are as substantial as its domestic sales, composing 6% of total merchandise exports by value. In 2023, pharmaceutical exports swelled to USD 27 billion from USD 19 billion in 2018, growing at an annual rate of 8%. Over 70% of these exports are formulations, with bulk drugs and intermediates making up about 20%. India also exports vaccines, biosimilars, and innovative products such as New Chemical Entities and New Biological Entities.

With over 10,000 manufacturing facilities, 3,000 pharmaceutical companies, and 650 US-FDA-compliant plants, India has established itself as a global pharmaceutical hub, being the largest supplier of generic medicines worldwide. Indian products are exported to nearly 200 countries, meeting around 50% of Africa’s and 40% of the United States’ demand for generics. India’s ability to produce high-quality, cost-effective medicines has earned it the title ‘pharmacy of the world’.

However, in terms of export value, India’s position is less dominant, ranking 11th globally with its pharmaceutical exports making up 3% of the total. With strong domestic demand, growing international exports, and innovations in the pharmaceutical sector, India’s industry is poised for substantial growth in the upcoming years.

Source: (ANI)

Related Posts

  • Pharma
  • July 14, 2025
  • 121 views
Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR

Following an announcement by the Indian Council of Medical Research (ICMR) and Panacea Biotec Limited to initiate third phase trials, about 8,000 of the targeted 10,000 participants have enrolled in…

  • Pharma
  • July 14, 2025
  • 118 views
In Gurgaon, illegal hospital busted, quack arrested in raid

Gurgaon: A team from the chief minister’s flying squad conducted a raid at a private hospital in Fazalwas village on Tuesday. According to police, Shivansh Hospital, located on the Tauru…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR

Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR

In Gurgaon, illegal hospital busted, quack arrested in raid

In Gurgaon, illegal hospital busted, quack arrested in raid

Customs delivers 25 containers of seized drugs to NAFDAC

Customs delivers 25 containers of seized drugs to NAFDAC

License Of Four Pharma Firms Cancelled For Illegal Drug Trade In Jammu & Kashmir

License Of Four Pharma Firms Cancelled For Illegal Drug Trade In Jammu & Kashmir